Specialty Management: Keeping Up with Runaway Innovation
Contact Hours: 1.5 | Activity Type: Knowledge-based | ACPE UAN: 0233-0000-18-069-L04-P
Current projections suggest that the amount of money spent on specialty drugs in the U.S. will more than quadruple from $87 billion annually in 2012 to $400 billion annually by 2020. Although specialty medications only account for about 1% of all prescriptions written, they account for more than 40% of the total drug spend. Often, these medications represent life-saving breakthroughs or provide substantial therapeutic improvement for patients, but as more and more specialty drugs are approved each year, payers are scrambling to find the resources to pay for these costly medications. Now, more than ever, it is imperative for payers to look ahead at what is coming down the specialty pipeline and to start planning their management strategies for when these agents reach the market. This session will provide an overview of promising specialty medications in development, including efficacy data, potential place in therapy, and anticipated budgetary impact.
At the completion of this activity, participants should be able to: